Significantly lower CYP2D6 metabolism measured as the O/N ‐desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10 : a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients-Reference-Cited by-同舟云学术

Significantly lower CYP2D6 metabolism measured as the O/N ‐desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10 : a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients

Published:2018-11-11 Issue:1 Volume:85 Page:194-201
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Haslemo Tore¹,Eliasson Erik²,Jukić Marin M.³⁴,Ingelman‐Sundberg Magnus³,Molden Espen¹⁵^ORCID

Affiliation:

1. Center for PsychopharmacologyDiakonhjemmet Hospital Oslo Norway

2. Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska InstituteKarolinska University Hospital Stockholm Sweden

3. Section of Pharmacogenetics, Department of Physiology and PharmacologyKarolinska Institute Stockholm Sweden

4. Department of Physiology, Faculty of PharmacyUniversity of Belgrade Serbia

5. Department of Pharmaceutical Biosciences, School of PharmacyUniversity of Oslo Oslo Norway

Funder

Vetenskapsrådet

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13788

Reference32 articles.

1. Polymorphic Cytochrome P450 Enzymes (CYPs) and Their Role in Personalized Therapy

2. The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP ) Allele Nomenclature Database

3. Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

4. Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

5. Prediction of CYP2D6 phenotype from genotype across world populations

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: Avoiding intolerance to antipsychotics through a personalized treatment approach based on pharmacogenetics;Frontiers in Psychiatry;2024-03-19

2. A consideration of CYP2D6 genetic variations in the Ghanaian population as a potential ‘culprit’ for the tramadol ‘abuse crisis’;BMC Medical Genomics;2024-01-22

3. Case report: application of pharmacogenetics in the personalized treatment of an elderly patient with a major depressive episode;Frontiers in Psychiatry;2023-08-07

4. Using population pharmacokinetic analyses of drugs metabolized by CYP2D6 to study the genotype–phenotype translation;Basic & Clinical Pharmacology & Toxicology;2023-06-04

5. Different Types of Naturally based Drug Delivery Carriers: An Explanation and Expression of Some Anti-cancer Effects;Current Pharmaceutical Design;2023-04